Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy.
Level 5 - mechanism / opinion, no new human data
Preclinical bench (in vitro) and animal (in vivo) study.
PubMed 32861192 · doi:10.1016/j.isci.2020.101453
What was done
In vitro assays evaluated fatty acid oxidation (FAO) utilization and the effects of FAO inhibitors across patient-derived glioblastoma cell lines. In vivo models assessed glioblastoma tumor growth and host survival following knockdown of carnitine palmitoyltransferase 1A (CPT1A, the rate-limiting enzyme for FAO) and under an unrestricted ketogenic diet.
What was found
The abstract reports directional findings without numerical values. In vitro, FAO inhibitors inhibited growth in nearly every patient-derived glioma cell line. In vivo, CPT1A knockdown reduced tumor growth rates and prolonged survival. In contrast, an unrestricted ketogenic diet failed to reduce tumor growth and significantly decreased survival in some animal models.
Why it matters
These findings challenge the assumption that glioblastomas rely solely on glycolysis and indicate that ketogenic diets may provide alternative fuels that sustain tumor growth and worsen survival in preclinical settings.
Limits
Findings are limited to preclinical in vitro and animal models, preventing direct clinical application. The abstract omits sample sizes, animal cohort counts, exact quantitative measurements, confidence intervals, and dietary formulations.
Cited by
- contradicts In every published paper claiming cancer cells can burn fatty acids and ketone bodies, glucose and glutamine were present in the media confounding the result.